Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Mon...(e of its products; (v) whether Tianshi E...)

Date:3/28/2008

e of its products; (v) whether Tianshi Engineering, the Company's affiliate which sells its products in China, obtains a direct selling license in China; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under "Search for Company Filings."

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE THREE MONTHS AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

REVENUE - RELATED

PARTIES $ 13,315,311 $ 16,587,160 $ 54,900,060 $ 66,790,466

COST OF SALES 4,546,711 4,367,702 16,526,695 18,082,441

GROSS PROFIT 8,768,600 12,219,458 38,373,365 48,708,025

SELLING, GENERAL AND

ADMINISTRATIVE

EXPENSES 3,953,263 4,148,297 14,306,660 12,789,810

INCOME FROM

OPERATIONS 4,815,337 8,071,161 24,066,705 35,918,215

OTHER (EXPENSE)

INCOME, NET 475,918 33,633 1,520,208 161,091

INCOME BEFORE

PROVISION FOR

INCOME TAXES

AND MINORITY

INTEREST 5,291,255 8,104,794 25,586,913 36,079,306

PROVISION FOR

INCOME TAXES 416,222 635,408 2,026,875 2,823,899

INCOME BEFORE

MINORITY

INTEREST 4,875,033 7,469,386 23,560,038 33,255,407

MINORITY INTEREST 995,606 1,566,759 4,966,397 6,963,330

NET INCOME 3,879,427 5,902,627 18,593,641 26,292,077
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
2. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
5. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
6. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
7. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
10. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
11. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia